Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-31

• Starpharma (SPL) secures regulatory approval for its VIRALEZE antiviral nasal spray in Malaysia
• The registration of VIRALEZE in Malaysia will allow Starpharma and its commercial partners to market and sell the product throughout the country, targeting a population of more than 33 million
• SPL’s registrations for the spray now spans more than 35 countries, including Europe and the UK
• Meanwhile, Starpharma has been conducting a post-market clinical study of VIRALEZE in the UK in patients with COVID-19 to examine the spray’s ability to reduce viral load over a seven-day period
• Starpharma is up 2.56 per cent, trading at 40 cents at 10:25 am AEST

This was released at the beginning of June last year. Since then 11 months has passed us by without a further word.

Note also the share price then and where it sits today.

Sound familiar?